Skip to main content
TipRanks
Go Ultimate75% OFF

Steep Hill Inc (GPIN) AI Stock Analysis

1 Followers
TSE:GPIN

Steep Hill Inc

(CNQX:GPIN)

Select Model
Rating:58Neutral
Price Target:CAD 0.06▼(-71.50% Downside)
Action:initiatedcoverage
Date:01/13/26

Poor financials from revenue absence and cash burn dominate as key risk, tempered by attractive low P/E valuation and stable technicals; score reflects high-risk early-stage pharma potential.

Positive Factors
Industry PartnershipsPartnerships with industry players and regulatory bodies enhance Steep Hill's credibility and revenue potential, supporting long-term business sustainability and compliance.
Negative Factors
Operational InefficienciesPersistent operational inefficiencies, as indicated by negative margins, suggest challenges in cost management and profitability, affecting long-term business viability.

Steep Hill Inc (GPIN) vs. iShares MSCI Canada ETF (EWC)

-100%-50%0%50%100%150%TSE:GPIN-39.21%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 889.83K
Dividend Yield
―
Average Volume (3M)
16.23K
Price to Earnings (P/E)
0.4
Beta (1Y)
0.83
Revenue Growth
―
EPS Growth
-150.05%
Country
Canada
Employees
6
Sector
Financial
Sector Strength
68
Industry
Drug Manufacturers - Specialty & Generic

Steep Hill Inc Business Overview & Revenue Model

Company Description

Steep Hill Inc., a cannabis science and technology company, provides laboratory testing, quality assurance, and data analytics services in Canada and the United States. It offers analytical testing services, such as cannabinoids, terpenes, pesticides...

How the Company Makes Money

null

Steep Hill Inc Financial Statement Overview

Summary

Weak income statement with no revenue and operating losses (score 25) drags down despite strong debt-free balance sheet (85) and modest cash flow (35); reflects early-stage pharma risks offset by equity strength.

Income Statement

25Negative

Balance Sheet

85Very Positive

Cash Flow

35Negative

Steep Hill Inc Technical Analysis

Technical Analysis SentimentNegative
Last Price0.20

Price Trends

50DMA0.22Negative
100DMA0.26Negative
200DMA0.31Negative

Market Momentum

MACD-0.01Negative
RSI53.05Neutral
STOCH87.50Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GPIN, the sentiment is Negative. The current price of 0.20 is above the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.22, and below the 200-day MA of 0.31, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 53.05 is Neutral, neither overbought nor oversold. The STOCH value of 87.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GPIN.

Steep Hill Inc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

TSE:GPIN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
TSE:GPINTSE:GPIN58NeutralCAD 8.11M0.3919.51%――-150.05%
TSE:LABSTSE:LABS55NeutralCAD 23.49M-9.23-7.66%―-9.31%66.84%
TSE:INNOTSE:INNO45NeutralCAD 8.05M-6.01-19.37%―-19.20%42.54%
TSE:ATLETSE:ATLE42NeutralCAD 37.30M-0.76-2099.75%―-96.13%88.13%
TSE:BNXTTSE:BNXT38UnderperformCAD 32.66M-2.91142.79%―――

* Financial Sector Average

Performance Comparison

-50%0%50%100%TSE:GPINTSE:ATLETSE:LABSTSE:BNXTTSE:INNODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:GPIN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:GPINSteep Hill Inc0.20-0.13-39.21%
TSE:ATLEWillow Biosciences0.08-0.07-46.67%
TSE:LABSMedipharm Labs (Otc)0.06-0.01-7.69%
TSE:BNXTBionxt Solutions Inc0.24-0.45-65.22%
TSE:INNOInnocan Pharma Corporation1.79-11.00-86.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Dec 30, 2025